Physician profile
Tammy R Spring
NPI 1083816722
$16,791.49
in general payments reported to CMS, 2019-2025
46 companies · $3,226 in 2025
The $3,226 reported for 2025 was more than what 79% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,739 · 2020: $1,488 · 2021: $1,439 · 2022: $2,331 · 2023: $2,658 · 2024: $2,910 · 2025: $3,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,619 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,618.75 |
| Education | $175.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,732.09 | 2019-2025 | Tavneos, Enbrel, Otezla |
| Janssen Biotech, INC. | $1,778.80 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $1,641.94 | 2019-2025 | Rinvoq, Skyrizi, Ubrelvy |
| Pfizer INC. | $1,459.96 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,271.98 | 2019-2025 | |
| Ucb, INC. | $1,012.15 | 2019-2025 | Bimzelx, Cimzia |
| Horizon Therapeutics Plc | $714.62 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $676.30 | 2021-2025 | Saphnelo |
| Ani Pharmaceuticals, INC. | $564.05 | 2022-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $511.85 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $504.53 | 2019-2024 | Taltz |
| Radius Health, INC. | $503.96 | 2019-2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $483.27 | 2019-2025 | Orencia |
| Mallinckrodt Hospital Products INC. | $372.15 | 2021-2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $322.42 | 2019-2025 | Strensiq, Soliris, Ultomiris |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Spring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.